Clinical Trial Update: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial evaluating the efficacy, safety, and tolerability of HZN-825 in idiopathic pulmonary fibrosis has been terminated, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• HZN-825

Snippet

Sponsor: Amgen | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2025-12-03